<DOC>
	<DOCNO>NCT00195572</DOCNO>
	<brief_summary>The purpose study verify non-inferiority survival time Isovorin/5-fluorouracil ( 1-LV/5FU ) therapy TS-1 therapy patient inoperable advanced recurrent gastric cancer . Secondary endpoint include response rate , duration response , time progression ( TTP ) safety quality life ( QOL ) .</brief_summary>
	<brief_title>Study Evaluating Isovorin Advanced/Recurrent Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Gastric cancer diagnose histologically cytologically Normal organ function bone marrow , heart , liver kidney Age 2077 Other inclusion applies Serious infection , heart disease , complication organ disorder Ongoing administration flucytosine Pregnant breastfeeding woman Other exclusion applies</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Advanced/Recurrent Gastric Cancer</keyword>
</DOC>